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Chagas disease is a severe illness, which can lead to death if the patients are not 
promptly treated. The disease is caused by the protozoan parasite Trypanosoma cruzi, 
which is mostly transmitted by a triatomine insect vector. There are 8–10 million peo-
ple infected with T. cruzi in the world, but the transmission of such disease by bugs 
occurs only in the Americas, especially Latin America. Chronically infected patients 
will develop cardiac diseases (30%) and up digestive, neurological, or mixed disorders 
(10%). Lysophosphatidylcholine (LPC) is the major phospholipid component of oxidized 
low-density lipoproteins associated with atherosclerosis-related tissue damage. Insect-
derived LPC powerfully attracts inflammatory cells to the site of the insect bite, enhances 
parasite invasion, and inhibits the production of nitric oxide by T. cruzi-stimulated mac-
rophages. The recognition of the ubiquitous presence of LPC on the vector saliva, its 
production by the parasite itself and its presence both on patient plasma and its role on 
diverse host × parasite interaction systems lead us to compare its distribution in nature 
with the title of the famous Beatles song “Here, There and Everywhere” recorded exactly 
50 years ago in 1966. Here, we review the major findings pointing out the role of such 
molecule as an immunosignaling modulator of Chagas disease transmission. Also, we 
believe that future investigation of the connection of this ubiquity and the immune role of 
such molecule may lead in the future to novel methods to control parasite transmission, 
infection, and pathogenesis.
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iNTRODUCTiON
Lysophosphatidylcholine (LPC) is a major regulator of several biological processes. It is produced 
by the hydrolysis of the fatty acid at sn-2 position of phosphatidylcholine (PC) catalyzed by phos-
pholipase A2 (PLA2) or alternatively by its transfer from PC to cholesterol by the action of another 
enzyme a cholesterol acetyltransferase (1–3). Such molecule was originally believed to play a role 
exclusively on membrane structure but their involvement on the pathogenesis of several human 
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diseases is increasingly clear in the last few years. Its recognition 
as a causative factor has occurred by mainly by two different set of 
data. The first line of evidence toward a functional and signaling 
role of LPC is due to the close link between plasma lipid profile 
and pro-oxidant reactions common in inflammatory diseases, 
especially in atherosclerosis. The second route of evidences lies on 
the effects of LPC on cells involved in innate immunity. We will 
discuss the growing of such concepts and how they overlap and 
support the role of such lysophospholipid in parasitic diseases as 
follows.
Lysophosphatidylcholine and the bioactive lipids lysophos-
phatidic acid (LPA), sphingosine-1-phosphate (S1P), and 
sphingosylphosphorylcholine (SPC) modulate a wide number 
of biological processes on mammalian cells. LPC has been clas-
sically involved in various physiological events and is already 
known as a central molecule in various pathological conditions 
but is especially present during the deposition and infiltration 
of inflammatory cells and deposition of atheroma, as discussed 
above (4–6). Research aimed at LPC increased substantially 
from the fact that these molecules are involved in atherosclerosis 
(7). The idea that several phospholipases secreted by circulating 
leukocytes may participate in this pathology was soon proposed. 
Thus, the current model suggests that diabetes and hypercholes-
terolemia contribute to generate a large number of low-density 
lipoprotein (LDL) particles in plasma, which can undergo oxida-
tion of unsaturated fatty acids, generating an oxidized particle 
(ox-LDL). Since on average, 50% of LDL fatty acids are arachi-
donic acid and linoleic acid, the chances of an oxidative event like 
this are huge. OxLDL is a potential cause of increased expression 
of inflammatory markers. TNF-α, MCP-1, and MCSF expression 
are increased by oxLDL and attract and differentiate monocytes 
to the lesion site. Accordingly, LPC is a powerful chemoattract-
ant molecule to macrophages. It is also generated by cells during 
apoptosis, as mentioned above. oxLDL particles are recognized 
by PLA2 secreted by different cells in plasma, including the 
types IIa, V, and X. In conclusion, plasma LPC is derived from 
the hydrolysis of PC mainly present in LDL and cell membranes 
by several different subfamilies of PLA2s usually following and 
oxidative event on its fatty acids.
Trypanosoma cruzi infects the vertebrate host through skin 
bites produced by bugs during their feed or by interaction with 
conjunctival mucosa. This interaction sometimes produces the 
Romaña signal or chagoma whose histology is defined by a 
large number of mononuclear cells (8). It is likely that T. cruzi 
stimulates skin cells to produce mediators that trigger a local 
inflammatory response. Chagas disease displays an acute phase, 
followed by a chronic phase where the parasites are physically 
linked to inflammation sites in the heart and esophagus (9–15). 
The disease is considered today as multifactorial once pathogen 
and host are continuously interacting throughout the whole 
patient life (16). Following the first 2–3 weeks of the vector bite, 
T. cruzi infection is manifested by a high load of parasites in the 
blood and tissues. Acute infection is characterized by a huge 
activation of the immune system. Such activation includes the 
production of high levels of cytokines, a large activation of T and 
B cells, lymphadenopathy, and splenomegaly. Also, it displays a 
visible inflammation due to the infection in tissue niches. The 
acute phase leads to the development of acquired immunity. 
Such mechanism ensures the effective control of parasitemia. 
The chronic phase takes place throughout the patient’s life and is 
associated with low levels of parasite in the host. The beginning 
of chronic infection in Chagas disease is asymptomatic in most 
patients. However, clinical manifestations will range from no 
symptoms to the involvement of the cardiovascular symptoms 
and/or gastrointestinal complications as the disease progresses 
(17, 18). The innate immune system appears to be essential for at 
least two important aspects of Chagas disease: control of parasite 
replication in host tissue and the progress of the inflammatory 
reaction. The inflammatory reaction itself may be a major cause 
of tissue damage and dysfunction of certain organs in the patient 
(18). Experiments in T. cruzi infection models have shown that a 
potent Th-1 CD4 and CD8 immune response controls parasitemia 
during the initial stage of the disease. Such immune response is 
characterized by the production of IFN-γ, TNF-α, and IL-12, as 
well as the production of nitric oxide (NO). Additionally, cells 
of innate immunity, such as “natural killer” (NK) cells, dendritic 
cells, and macrophages, are also key factors in the initial control 
parasite replication (11, 17, 19).
In recent years, research on Chagas disease has focused on 
the investigation of the role of pathogen-associated molecular 
patterns (PAMPs) protozoa, which are the targets of the innate 
immune response receptors. Also the problem of identification 
of relevant receptors for the innate immunity to the parasite 
during the course of the disease in the host has been addressed 
by several laboratories. This strategy ultimately aimed at develop-
ing therapeutic interventions through the use of derivatives of 
PAMPs present in the parasites. Glycosyl-phosphatidylinositol 
(GPI) is the name given to the first glycoconjugate identified 
in Trypanosoma brucei. This molecule was identified with the 
function of anchoring proteins on the cell surface (20–23). T. 
cruzi express on their surface glycoproteins anchored by GPIs 
(20–23). GPI anchors from trypomastigotes include mucin-like 
glycoproteins (mucin-GPI) and are key molecules responsible for 
stimulating the host’s immune system (24–27). These mucin-GPIs 
activate macrophages and lead to the synthesis of proinflamma-
tory cytokines, chemokines, and NO (28). The innate immune 
response to T. cruzi infection largely results from the activation 
of signaling pathways triggered by Toll-like receptors (TLRs).
Toll-like receptors recognize conserved structural motifs pre-
sent on different pathogens. Following their activation, TLRs trig-
ger intracellular signaling cascades that build up the host immune 
response (18, 29). There are 10 TLRs described in human and 12 in 
mice (18, 29). GPI-induced stimulus occurs during the initial phase 
of infection, where macrophages respond to trypomastigotes in a 
TLR-dependent mechanism. At this point in time the production 
of IL-12, TNF-α and the activation of CD4 and CD8 responses 
through IFN-γ will take place (30). TNF-α and IFN-γ-activated 
macrophages seems to have an important role in the control of 
parasite growth. Anchors free of proteins or GPI or glicoinositol 
phospholipids (GIPLs) are also able to stimulate the host immune 
system. GIPLs are similar to GPIs but contain ceramide in their 
lipid portion (24, 25). TLRs 2, 4, and 9 are the main TLRs involved 
in the innate immune response to T. cruzi (24, 31–36). TLR2 was 
found to be activated by mucin-GPI (24, 31–36). The heterodimer 
FiGURe 1 | Here, there, and everywhere. This cartoon depicts the major findings in recent years regarding the role of LPC on infectious diseases. Here, originally 
found as a vector, salivary phospholipid able to modulate Chagas disease through the suppression of NO production. There, LPC was recently described as the 
product of parasite synthesis. Everywhere, several reports have involved LPC on different aspects of parasitic diseases but also a relevant mediator molecule used 
to subvert the prey by hunting insects. Finally, its role as a major component of snake venom is also shown.
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composed of TLR2 and TRL6 receptor is activated by GPI mucin 
and its co-receptor CD14 (34). T. cruzi GIPL activates the inflam-
matory response via TLR4. It induces neutrophil recruitment to 
the peritoneal cavity of mice and this effect is partly dependent on 
IL-1β production (32, 36). The T. cruzi genomic DNA also plays an 
important role in the vertebrate host proinflammatory response. 
Finally, TLR 9 is activated by CpG motifs in non-methylated DNA 
(34, 35). In the innate immune response mediated by TLRs, T. 
cruzi can also stimulate a TLR-independent response leading 
to the production of IFN-β and IFN-γ. This is due a rise on 
intracellular calcium concentration that activates calcineurin and 
calmodulin-dependent proteins (37–39).
HeRe: LPC-MeDiATeD HANDLiNG OF 
iNNATe iMMUNiTY AT THe SiTe OF 
PARASiTe iNFeCTiON
Our group demonstrated, for the first time, the presence 
of phospholipids and lysophospholipids in saliva and stool 
hematophagous organism Rhodnius prolixus, a triatomine vector 
of Chagas disease (40, 41). Such finding engaged salivary LPC 
into the host plasma environment and uncovered its role as both 
an anti-hemostatic and immunomodulatory molecule. The main 
lipids present in the saliva of R. prolixus are PC and LPC (40, 41). 
Salivary LPC is an additional anti-hemostatic molecule that is part 
of the pharmacological arsenal injected into the bite site to allow 
the insect feeds. It inhibits platelet aggregation and increases the 
production of NO in endothelial cells. Thus, the LPC was origi-
nally described as a molecule with antiplatelet and vasodilatory 
activity, and few years later, its effect as an immunomodulator 
of T. cruzi infection has been demonstrated (40, 41) (Figure 1).
The role of LPC as a modulator of T. cruzi infection is caused 
by three main mechanisms summarized as follows:
 1. LPC is a vector-derived molecule. Following attraction of 
inflammatory cells to the insect bite site, it enhances the 
chance of infection by the latter arrival of T. cruzi (40, 41).
 2. LPC produces a surge on intracellular calcium concentrations 
in macrophages. This will also enhance parasite invasion. It 
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also modulates the phosphorylation of key signaling mol-
ecules such as mitogen-activated kinases (MAPKs) (41, 42).
 3. LPC inhibits the production of NO by T. cruzi-stimulated 
macrophages, lipopolysaccharide (LPS), or LPS in the pres-
ence of IFN-γ. Thus, it handles the immune system of the 
vertebrate host (41, 42).
Such findings implied that LPC is a multifactorial signaling 
molecule, with signaling, anti-hemostatic, and immune effects on 
the context of Chagas disease transmission (43–46). The establish-
ment of infection by T. cruzi depends on the initial invasion of 
these cells by the parasite (47–49). This leads to the assumption 
that the salivary LPC can facilitate parasitic infection, favoring 
not only insect feeding but also the preparation of macrophage 
susceptibility for the arrival of the parasite, minutes or hours after 
the initial bite. Salivary LPC injection into the host’s skin followed 
by inoculation of the parasite leaded to an increase of threefold to 
sixfold on blood parasitemia (41). LPC effect on parasitemia relies 
on the activation of macrophage chemotaxis and suppression of 
NO synthesis. We also show an increase in parasite loads within 
macrophages induced by either 500-fold diluted saliva or LPC. 
Such results were the first demonstration of a factor able to poten-
tiate the transmission of Chagas disease and the first implication of 
a lysophospholipid as a modulator of an infectious disease (41, 42).
Activation of TLRs on host cells and the production of TNF-α, 
IL-12, and NO, required the adapter protein MyD88 (20–24, 30). 
TLRs 2, 4, and 9 have been implicated in the control of T. cruzi 
infection (20–24, 30). The involvement of TLR2 in the interaction 
between the parasite and macrophages was also demonstrated (24, 
30). TLR2 expression is essential for the induction of IL-12, TNF-
α, and NO. This receptor is activated by the parasite molecules, 
such as GPI anchors, that are isolated from the surface trypomas-
tigotes of T. cruzi. Curiously, IL-12 synthesis in macrophages 
exposed to T. cruzi is not affected by saliva (41). Interestingly, in 
bone marrow derived macrophages derived from TLR2-deficient 
mice IL-12 production is largely suppressed by LPC (41). These 
data indicate that in some types of cells this cytokine production 
can be affected by LPC through a TLR2-independent mechanism.
Furthermore, T. cruzi GIPLs are TLR4 agonists with proin-
flammatory effects (32, 36). We have shown that NO production 
induced by the parasite or LPS, another ligand of TLR4 or in 
peritoneal murine macrophages or bone marrow-derived mac-
rophages is blocked in both cases, the LPC even in the presence of 
IFN-γ vitro (41). The LPC’s ability to reverse the induction of NO 
production in every case, almost regardless of the type of ligand 
suggests that this bioactive lipid should act on a single pathway. 
Usually, LPC-sensitive receptors exhibit remarkable overlap in 
their specificity to the ligands they interact with and vice  versa. 
Different receptors have been proposed for LPC. This includes 
G2A a G protein-coupled receptor, and GPR4, another important 
candidate (50). It is noteworthy the low reproducibility of LPC stud-
ies where radioactive lipids were used. Together with the capacity 
of G2A to bind to fatty acids and protons, such findings brought 
a high complexity to this field (51). Thus, G2A is still recognized 
as the most known receptor to convey signals mediated by LPC 
presence in the chemical environment of cells. The redistribution 
of G2A receptor itself and the exposure of TLR4 on cell surface are 
highly influenced by LPC metabolism (51, 52). In this latter case, 
intracellular LPC amount is under control due to the activity of 
LPC-acyltransferase (LPCAT). This enzyme uses LPC to produce 
phospholipids. The incubation of monocytes with LPS activates the 
enzyme and increases the transport of TLR4 to cell-membrane rafts 
(52). The LPCAT inhibitor, thiophenyl 5-hydroxyethyl 5′3 pyridine 
(HETP), increases the ratio LPC/PC while it reverses the effect of 
LPS. Thus, T. cruzi may promote a redistribution of G2A and TLR4 
on cell surface during infection. This should be investigated in the 
future by both proteomic and immunological approaches.
In apoptotic cells, LPC is generated by a PLA2- calcium-
independent activated caspase-3. LPC then attracts phagocytes to 
cells and represents a sign of recognition of ongoing apoptosis (50, 
53, 54). LPC-induced chemotaxis in Chagas’ disease is intriguing 
once the uptake of apoptotic cells by macrophages infected with 
T. cruzi parasite stimulates their growth (55). Furthermore, the 
infective stages of T. cruzi are capable of generating lipid mes-
sengers, including LPC, that modulate the signaling of the host 
cell (56). LPC activates some protein kinase C isoforms (57). It 
is probably that different PKC isoforms are activated in different 
cell types. Also, when combined with different types of TLRs and 
adapters, the LPC-mediated signaling repertoire may produce a 
specific and yet to be studied particular mechanism of immuno-
suppression (Figure 1).
In order to evaluate some of these questions, we have addressed 
the role of LPC on TLR-mediated signaling pathway using HEK 
293A cells. Such cells were transfected with TLRs constructs and 
stimulated with LPCs displaying different fatty acid chain lengths 
and saturation levels (42). All tested LPCs activated both TLR4 
and TLR2-1 signaling pathways. Such results were confirmed 
through the evaluation of NF-κB activation and IL-8 production. 
Similar results were obtained when using peritoneal murine mac-
rophages. These cells responded to LPC stimulation by displaying 
NF-κB translocation. Curiously, when incubated in the presence 
of LPS, LPC counteracted several features of TLR4 signaling. In 
this case, NF-κB translocation, NO synthesis, and the expression 
of inducible nitric oxide synthase (iNOS) were blocked. Such 
phenotypes occur concomitantly with a hierarchical activation of 
the MAPKs p38 and JNK, but not ERK, in murine macrophages. 
Also, LPC blocked LPS-induced ERK activation in peritoneal 
macrophages but not in TLR-transfected cells. Such results indi-
cated that LPC behaves as a proinflammatory molecule in the 
absence of traditional TLR ligands. However, when LPS and LPC 
are present at the same time, a partial silencing of the canonical 
TLR4 pathway takes place. Such silencing involves the downregu-
lation of ERK pathway and does not affect p32 and JNK. Under 
these conditions, LPC assumes an anti-inflammatory phenotype 
through yet unknown ligands on cell surface (42).
THeRe: LPC iS SYNTHeSiZeD BY 
TRYPANOSOMATiD PARASiTeS
Phosphatidylcholine and LPC are synthesized by T. cruzi (58, 59), 
T. brucei (60), Leishmania spp. (61, 62), as well as by the malaria 
parasite, Plasmodium falciparum (63). Intriguingly, more than 
50% of the total lipids secreted by T. cruzi were identified as PC 
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and LPC (58). Recently, we have purified and structurally charac-
terized a C18:1-LPC in T. cruzi, which present a platelet-activating 
factor (PAF)-like activity, as it aggregates rabbit platelets (59). 
Comparable to PAF, platelet aggregation was completely blocked 
by the PAF receptor antagonist, WEB 2086. Considering that 
increased platelet aggregation related to myocarditis is observed 
in Chagas disease, it is possible that C18:1-LPC is an important 
lipid mediator in the progression of this disease. Nevertheless, 
what functions endogenous T. cruzi LPC have in the infection is 
yet to be unveiled. Such findings enhance our view that during 
the complete cycle of trypanosomatids transmission LPC will be 
able to handle surrounding cells, therefore enhancing parasite 
survival (Figure 1).
eveRYwHeRe: ROLe OF LPC iN OTHeR 
PARASiTiC iNFeCTiONS
In recent years, our group and others have explored the role of 
lysophospholipids, and especially LPC on the transmission and 
pathogenesis of different parasitic diseases. Also, it was demon-
strated that LPC plays a role on prey × predator. Such models lead 
us to the view that LPC is a ubiquitous modulator of host–parasite 
interaction (Figure 1).
Leishmaniasis
A key step on Leishmania infection is the invasion of macrophages, 
which usually occurs through an endocytic process. Such process 
leads to the formation of the parasitophorous vacuole (PV) that 
will harbor the parasite. PV was isolated from Leishmania-infected 
macrophages, and the analysis of its phospholipid composition 
was conducted (64). The levels of LPC increased as compared 
with non-infected cells. Such results were obtained by allowing 
either the promastigote or amastigote forms of the parasite to 
interact with macrophages previously labeled with radioactive 
phosphate. Thus, these findings indicate that following invasion 
there is a remodeling of host cell phospholipids, which enhances 
the production of LPC. The results obtained in the T. cruzi model 
(41, 42), where LPC was pointed out as a negative modulator of 
NO production suggest that Leishmania-induced remodeling 
of PV may handle the microbicide production and protects the 
parasite. If this mechanism is essential to allow parasite escape 
from PV should be investigated in the future. It is important to 
consider that the use of miltefosine, the first orally active anti-
leishmanial drug when directly used to treat Leishmania dono-
vani promastigotes, induced at higher doses the increase on LPC 
production on total parasite membrane extract, probably due to 
the activation of PLA2s (65). Curiously, such effect is confined 
to some specific membranar structure of the parasite since it 
is lost when the plasma membrane is evaluated separately. The 
involvement on LPC on Leishmania-infected was recently busted 
by the finding that such molecule in BALB/c mouse-derived DC 
infection (66). LPC enhanced by 92% the infection index was cor-
related to a delay on cell maturation as evaluated by the expression 
of CD86+/CD11c+. Treatment of such cells with LPS displayed 
the opposite effects. Also, the authors found that LPC reversed 
the immune balance between IL-10, TNF-α, and IL-6 once it 
induced a huge increase on the first cytokine while not affecting 
of slightly reducing the proinflammatory ones (66). Finally, they 
observed that LPC is also able to selectively increase arginase1 
expression by 395%. This enzyme is commonly induced by Th2 
cytokine response set and enhances parasite proliferation. Such 
effect is paralleled by a suppression of iNOS activation, which 
keeps the levels of the NO quite low in Leishmania-infected cells. 
Indoleamine 2,3-dioxygenase (IDO) catalyzes tryptophan catab-
olism through kynurenine pathway. The depletion of tryptophan 
blocks parasite proliferation. Leishmania and LPC induced IDO 
activation, which usually leads to the accumulation of kynurenine 
metabolites blocking Th1 response. Also, the increase on arginase 
expression and downregulation of iNOS production depletes 
invaded cells of GSH, which induced acute oxidative stress. LPC 
has recently been described as a major inducer of macrophage 
polarization toward the M2 phenotype (67–69). In monocytes 
obtained from patients with Post Kala-Azar Dermal Leishmanisis 
(68), it was noticed a strong downregulation of TLR2/4 receptors 
and an increased expression of PPAR-γ and arginase-1. Also, IL-4, 
IL-10, and IL-13 were significantly raised as compared to healthy 
individuals. Finally, it increased classical M2 markers CD206, 
arginase-1, and PPARG in monocytes. Such findings strongly 
demonstrate that M2 polarization of macrophages is a hallmark 
of Leishmania infection in vivo and suggest that a bridge to the 
LPC-induced effects is the next step toward the development of 
drugs that modulate disease chronicity. These drugs should be 
anti-leishmanial molecules that ensure the repolarization of M2 
macrophages toward the M1 proinflammatory and protective 
phenotype (68).
Human African Trypanosomiasis
A global metabolic profiling of plasma of patients carrying T. 
brucei rhodesiense [human African trypanosomiasis (HAT)] was 
performed and differences in the lipid, amino acid and metabolite 
profiles were identified. The most striking difference between the 
HAT patients and the control group was that six significantly 
altered amounts of LPC species were lower in patients than in 
controls (69). The interpretation of these data suggests that even 
though T. brucei rhodesiense is known to synthesize LPC de novo, 
the parasite probably scavenges several lipids from the host, as 
needed. Bearing in mind the results from our group on the key 
roles LPC play in T. cruzi infection, it is not surprising that LPC 
most likely engage crucial functions in other diseases caused by 
trypanosomatids.
Schistosomiasis
The first connection between LPC and the biology of schistoso-
miasis was noticed by the modifications on lipid plasma composi-
tion in infected patients (70). Curiously, in the plasma of infected 
hamsters, the levels of LPC are similar in both control and infected 
patients but major differences were found in the composition 
of the fatty acid acyl chains (71). LPC fatty acid composition 
showed a decrease on 18:2 and 20:5, but less marked changes in 
20:4 (71). Usually, human red blood cells (RBCs) are lysed by 
schistosomula of Schistosoma mansoni. LPC-derived from the 
parasite is used to lyse RBCs (72). The source of this LPC is prob-
ably the parasite itself once schistosomula synthesize LCP and 
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release it in the culture medium as evaluated with experiments 
using [3H]-phospholipids (72). The dynamics of such process was 
further through the use of precursors to label phospholipid and 
neutral lipid with the use of acyl chains ([3H]palmitic acid and 
[3H]oleic acid) or phospholipid polar head groups ([3H]choline 
and [14C]ethanolamine) (73). Schistosomal-derived lipids and 
LPC were shown to stimulate macrophages in vitro and induced 
TLR2-dependent NF-κB activation and cytokine production 
(74). Administration of LPC induced eosinophil recruitment 
and cytokine production, in a mechanism largely dependent on 
TLR2. Thus, parasite-derived LPC mediated key events on the 
pathogenesis and lethality of schistosomiasis.
everywhere
The use of LPC on host ×  parasite interaction seems to be a 
ubiquous strategy to allow the handling of intracellular signal-
ing pathways. Indeed, LPC may be a handful molecule also 
used by predators while hunting their daily meal. Snakes and 
bugs contain lysophospholipids in their saliva (75), Belostoma 
anurum saliva. This predator insect injects its saliva into the prey, 
which becomes immobilized (76). LPC isolated from saliva is 
neuroparalytic in vitro and in vivo (76), and it is highly likely that 
induce membrane depolarization and calcium entry into sensory 
nerves (76, 77). Indeed, LPC represents 25% of the total phos-
pholipids present in the saliva of such insect. Since Belostoma 
employs extra-oral digestion LPC also helps in the digestion of 
preys larger than this insect such as amphibians and small fishes. 
Thus, it was shown that LPC have paralytic activity in zebrafish, 
which was the first evidence that lysophospholipids might play an 
important role in prey immobilization (76). Lysophospholipids 
and specially LPC paralyze the neuromuscular junction and are 
also present on snake venoms (78, 79). LPC can also modulate the 
activity of NK cells (79). Indeed, snake presynaptic phospholipase 
A2 neurotoxins are commonly present on snake venoms. Mass 
spectromic analysis of the lipids resulting from SPAN action 
demonstrated several forms of LPC including myristoyl-LPC 
and fatty acids (77). Altogether the above finding suggest that 
LPC use both as a immune and neuromodulator is an ancient 
biochemical and pharmacological use for such molecule, which 
probably arose from the eventual leak of modified phospholipids 
from membranes of interacting organisms whether in the mam-
malian × protozoan model or in the insect × protozoan model 
(80, 81).
CONCLUSiON
In the future, drugs that target LPC of the signaling systems con-
veying LPC-mediated signals may largely affect the transmission 
and pathogenesis of several of the above mentioned diseases. 
The development of such drugs has been hampered by the yet 
unknown true LPC receptor. A functional analysis of novel LPC 
receptor candidates and the test of hypothesis regarding the 
parasite receptor recently described will provide a wider view 
of the potential of such molecule to trigger investigations in this 
area. It is quite interesting that the potential possibility of LPC 
modulates the several steps of TLR-mediated signaling or the 
interaction of this cascade with downstream effectors. Due to 
its major role as a suppressor of NO production in the presence 
of LPS, it is likely that LPC mechanism of action provides a 
novel system to understand the functionality of still unknown 
transcriptional factors as well as the hierarchical mechanism of 
MAPK regulation. It is quite challenging to imagine that the pre-
viously known structural phospholipids are yet a potential source 
of yet not completed understood signaling modules. The seminal 
discover of lysophospholipid role in human atherosclerosis 
combined with its potential selection as an immunosupressor, 
pharmacological, and neurological modulator by bugs, parasites, 
worms, and snakes leads to an increase interest on how far the 
ubiquity of such molecules has been shaped during evolution. 
The detailed investigation of such models at the molecular level 
in the future will certainly provide in the near future several 
novel targets for blocking the transmission and pathogenesis of 
such diseases.
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